These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29980054)

  • 41. 10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes.
    Belhassen M; Van Ganse E; Nolin M; Bérard M; Bada H; Bruckert E; Krempf M; Rebours V; Valero R; Moulin P
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1332-e1342. PubMed ID: 33221907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity.
    Brisson D; Larouche M; Chebli J; Khoury E; Gaudet D
    Clin Biochem; 2023 Apr; 114():67-72. PubMed ID: 36780934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
    Chaudhry R; Viljoen A; Wierzbicki AS
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Hegele RA
    touchREV Endocrinol; 2022 Nov; 18(2):82-83. PubMed ID: 36694895
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of primary hypertriglyceridemia states--General approach and the role of extracorporeal methods.
    Stefanutti C; Julius U
    Atheroscler Suppl; 2015 May; 18():85-94. PubMed ID: 25936310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A three month-old infant with severe hyperchylomicronemia: molecular diagnosis and extracorporeal treatment.
    Stefanutti C; Gozzer M; Pisciotta L; D'Eufemia P; Bosco G; Morozzi C; Papadia F; Shafii M; Di Giacomo S; Bertolini S
    Atheroscler Suppl; 2013 Jan; 14(1):73-6. PubMed ID: 23357145
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Familial lipoprotein lipase deficiency caused by known (G188E) and novel (W394X) LPL gene mutations.
    Hooper AJ; Crawford GM; Brisbane JM; Robertson K; Watts GF; van Bockxmeer FM; Burnett JR
    Ann Clin Biochem; 2008 Jan; 45(Pt 1):102-5. PubMed ID: 18275685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.
    Meyers CD; Tremblay K; Amer A; Chen J; Jiang L; Gaudet D
    Lipids Health Dis; 2015 Feb; 14():8. PubMed ID: 25889044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The burden of familial chylomicronemia syndrome from the patients' perspective.
    Gelrud A; Williams KR; Hsieh A; Gwosdow AR; Gilstrap A; Brown A
    Expert Rev Cardiovasc Ther; 2017 Nov; 15(11):879-887. PubMed ID: 28847199
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Type I hyperlipidaemia caused by lipoprotein lipase deficiency in a nurseling: the role of the clinical laboratory in processing biological samples and contributing to the diagnosis and therapeutic follow-up of patients.
    Girard JM; Debailleul PA; Chaillou E; Benlian P; Larcher F; Simard G; Reynier P; Homedan C
    Ann Biol Clin (Paris); 2015; 73(5):581-6. PubMed ID: 26489817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A case of severe acquired hypertriglyceridemia in a 7-year-old girl.
    Lilley JS; Linton MF; Kelley JC; Graham TB; Fazio S; Tavori H
    J Clin Lipidol; 2017; 11(6):1480-1484. PubMed ID: 28916403
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants.
    Perera SD; Wang J; McIntyre AD; Dron JS; Hegele RA
    J Clin Lipidol; 2023; 17(1):87-93. PubMed ID: 36476373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipoprotein lipase deficiency: clinical, biochemical and molecular characteristics in three patients with novel mutations in the LPL gene.
    Kolářová H; Tesařová M; Švecová Š; Stránecký V; Přistoupilová A; Zima T; Uhrová J; Volgina SY; Zeman J; Honzík T
    Folia Biol (Praha); 2014; 60(5):235-43. PubMed ID: 25863041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome.
    Cefalù AB; Giammanco A; Noto D; Spina R; Cabibi D; Barbagallo CM; Averna M
    Endocrine; 2021 Feb; 71(2):344-350. PubMed ID: 33006726
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Familial chylomicronemia syndrome. A sixty year follow-up in two siblings and their kindreds. Nosological and clinical considerations.
    Vigna GB; Citroni N; Tarugi P; Fellin R
    J Clin Lipidol; 2022; 16(5):591-595. PubMed ID: 35945124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency.
    Burnett JR; Hooper AJ
    Curr Opin Mol Ther; 2009 Dec; 11(6):681-91. PubMed ID: 20072945
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-Alcoholic Fatty Liver in Patients with Chylomicronemia.
    Maltais M; Brisson D; Gaudet D
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33572376
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification and Characterization of Two Novel Compounds: Heterozygous Variants of
    Wang S; Cheng Y; Shi Y; Zhao W; Gao L; Fang L; Jin X; Han X; Sun Q; Li G; Zhao J; Xu C
    Front Endocrinol (Lausanne); 2022; 13():874608. PubMed ID: 35923617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Familial chylomicronemia syndrome: pediatric experience in Argentina].
    Araujo MB; Eiberman G; Etcheverry N; Pacheco G
    Arch Argent Pediatr; 2022 Jun; 120(3):e123-e127. PubMed ID: 35533124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypertriglyceridaemia: an update.
    Wierzbicki AS; Kim EJ; Esan O; Ramachandran R
    J Clin Pathol; 2022 Dec; 75(12):798-806. PubMed ID: 35710321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.